Mohamad Makhzoumi, identified as a roughly 10% owner of Korro Bio, Inc. (NASDAQ: KRRO), increased his stake in the company through a purchase disclosed on a Form 4 filed with the Securities and Exchange Commission. The filing shows that on March 10, 2026, Makhzoumi acquired 207,100 shares of Korro Bio common stock at $11.11 per share, for a total transaction value of $2,300,881.
Alongside the common shares, the transaction included the purchase of 242,945 Pre-Funded Warrants at a price of $11.109 each. After the completion of these purchases, Makhzoumi indirectly holds 1,297,893 shares of Korro Bio. At the time of reporting, the company’s market capitalization stood at $113.79 million and the stock was trading at $11.50. The share price has suffered significant depreciation over the past six months, falling 62.61%, even as it shows a year-to-date rebound of 43.57%.
Separately, Korro Bio disclosed a private investment in public equity financing that is expected to generate approximately $85 million in gross proceeds. The financing round is led by Venrock Healthcare Capital Partners and includes participation from a group of new and existing investors. The company presented details of its programs and pipeline during a recent Virtual Analyst Day, where it discussed investigational approaches focused on Urea Cycle Disorders and Hepatic Encephalopathy.
Following the financing announcement and the Virtual Analyst Day, several sell-side firms revised their recommendations and price targets for Korro Bio. Clear Street moved its rating to "Buy" from "Hold," setting a price target of $18.00 and citing the potential of the company’s new lead program addressing hyperammonemia. H.C. Wainwright also raised its view to "Buy," assigning a $20.00 price target and highlighting the prospects for Korro’s RNA editing candidate, KRRO-121. Piper Sandler upgraded the stock to "Overweight" and increased its price target to $30.00.
The insider purchase, announced financing expectations, and subsequent analyst upgrades occurred within the same informational window for the company. Each element appears in regulatory or company-disclosed filings and communications: the Form 4 documents the insider transaction; company disclosures describe the PIPE expected to bring in about $85 million led by Venrock Healthcare Capital Partners; and the analyst actions and price targets were issued after the company’s Virtual Analyst Day presentation.
Investors and market participants tracking Korro Bio can point to the combination of an insider adding shares, a planned capital raise led by a healthcare-focused investor group, and renewed broker-dealer interest as notable developments in the company’s near-term story. The company’s recent market metrics - an $11.50 share price, a six-month decline of 62.61%, and a YTD recovery of 43.57% - provide additional context for how these developments are being priced by the market.
Context and next steps
The Form 4 filing establishes the timing and magnitude of the insider purchase. The PIPE is described as expected to generate approximately $85 million in gross proceeds and is noted as being led by Venrock Healthcare Capital Partners with participation from multiple new and existing investors. The analyst upgrades and price-target changes followed the Virtual Analyst Day, where the company outlined its therapeutic focus on Urea Cycle Disorders and Hepatic Encephalopathy and discussed the KRRO-121 RNA editing program.